Previous 10 | Next 10 |
Gainers: Endurance International (EIGI) +61%.Superior Industries International (SUP) +35%.DBV Technologies (DBVT) +32%.Renren (RENN) +22%.Digital Ally (DGLY) +21%.Dunxin Financial (DXF) +19%.Par Pacific Holdings (PARR) +18%.Tricida (TCDA) +18%.Lumber Liquidators (LL) +17%.Vislink Technol...
Shares of Jounce Therapeutics (NASDAQ: JNCE) were crashing 20.2% lower as of 11:42 a.m. EST on Monday. The big drop came after the company announced that it would not continue patient enrollment in the Emerge phase 2 trial evaluating vopratelimab (vopra) in combination with Bristo...
Gainers: DBV Technologies (DBVT) +61%, AnPac Bio-Medical Science (ANPC) +16%, Community Health Systems (CYH) +15%, ProPhase Labs (PRPH) +12%, ZIOPHARM Oncology (ZIOP) +10%.Losers: Liquidia Technologies (LQDA) -28%, Jounce Therapeutics (JNCE) -...
Early data evaluation of EMERGE Phase 2 trial evaluating Jounce Therapeutics' (JNCE) vopratelimab in combination with ipilimumab in PD-(L)1 inhibitor experienced non-small cell lung cancer ((NSCLC)) patients, suggests that the trial will not meet pre-specified interim criteria for c...
- No further enrollment in EMERGE trial of v opratelimab in combination with ipilimumab based on interim analysis - - First patient dosed in SELECT trial of v opratelimab in c ombination with JTX-4014 in i...
CAMBRIDGE, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2020 financial results...
Gainers: Arrowhead Pharmaceuticals (NASDAQ: ARWR ) +47% . More news on: Arrowhead Pharmaceuticals, Inc., Eastman Kodak Company, Myomo, Inc., Stocks on the move, , Read more ...
Gainers: Novus Therapeutics (NASDAQ: NVUS ) +162% . More news on: Novus Therapeutics, Inc., Marinus Pharmaceuticals, Inc., Plus Therapeutics, Inc., Stocks on the move, , Read more ...
Jounce Therapeutics ( JNCE ) is a small biotechnology company focused on the rapidly expanding industry of immuno-oncology. Armed with a productive drug discovery platform, a unique mid-stage lead candidate in lung cancer, and a penchant for striking lucrative deals with big pharma, the future...
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in fireside cha...
News, Short Squeeze, Breakout and More Instantly...
Jounce Therapeutics Inc. Company Name:
JNCE Stock Symbol:
NASDAQ Market:
Jounce Therapeutics Inc. Website:
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Co...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or t...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE)...